Thursday, March 19, 2026

Spotlight on Exercise Oncology

Redefining Cancer Care through Exercise Oncology


In today’s rapidly evolving healthcare landscape, innovation is no longer confined to pharmaceuticals, surgical techniques, or diagnostic breakthroughs. Increasingly, a powerful yet often underutilized tool is gaining recognition within oncology: exercise as medicine. At the forefront of this movement is Christopher Fitzmaurice, MS, CEP, CSCS, CET, a clinical exercise physiologist at the University of Miami Health System whose work is helping reshape how cancer patients and survivors approach recovery, resilience, and long-term health.

With credentials that span clinical exercise physiology, strength and conditioning, and cancer-specific training, Fitzmaurice represents a new generation of healthcare professionals bridging performance science with medical care. As a Certified Cancer Exercise Trainer (CET) and Certified Strength & Conditioning Specialist (CSCS), his expertise lies not only in optimizing physical performance, but in translating that knowledge into meaningful, life-enhancing outcomes for individuals navigating one of the most challenging diagnoses imaginable.

 

From Clinical Practice to Purpose-Driven Mission

Currently working within the executive health and concierge medicine program at the University of Miami, Fitzmaurice’s journey was shaped by his earlier tenure at the Sylvester Comprehensive Cancer Center, where he spent several years working directly with cancer patients and survivors. It was here that his professional path evolved into a mission.

“My mission is to make exercise the standard of care—not just for some, but for all, and especially for cancer survivors.”  While many practitioners enter oncology through traditional clinical routes, Fitzmaurice’s perspective was informed by both personal and professional experiences. Having lost family members to cancer, he carried a personal connection to the disease. However, it was his hands-on clinical exposure that crystallized his purpose.

“I’ve always been connected to cancer through family, but I didn’t become truly passionate until I started working directly with patients and saw the need firsthand.”

 

Exercise Oncology: From Concept to Clinical Reality


Exercise oncology has undergone a remarkable transformation over the past decade. Once viewed as supplementary or optional, it is now supported by a growing body of evidence demonstrating its clinical value. 
Fitzmaurice has been both a witness to and a contributor within this expanding field. “We’ve seen an explosion in randomized clinical trials—nearly a 300% increase—showing how exercise can dramatically impact cancer survivors.”

These studies have revealed that structured exercise can reduce treatment-related side effects, improve cardiovascular and muscular function, enhance mental well-being, and support overall quality of life. More importantly, exercise is now being examined not just as recovery, but as a therapeutic intervention throughout the cancer journey.

 

Beyond Rehabilitation: A Continuum of Care

Historically, physical rehabilitation in oncology was largely reactive—focused on helping patients recover from surgery or treatment-related impairments. Fitzmaurice is part of a growing movement that challenges this limited framework. “Exercise is no longer just something we think about after treatment. We now understand its value during treatment and even before it—what we call prehabilitation.”

This shift introduces a continuum of care: exercise before treatment to build resilience, during treatment to maintain function, and after treatment to support recovery and long-term health. “Rehabilitation helps treat the burden of disease, but exercise helps maintain function and improve outcomes over time.”

During the COVID-19 pandemic, Fitzmaurice expanded this model through telehealth, delivering both individual and group-based exercise programs to patients who were otherwise isolated from care. “The impact wasn’t just physical—it was mental as well. You could see how much it meant for patients to stay active and engaged.”

 

Advocacy and Addressing Hidden Challenges

Courtesy of: Scott Baker

Beyond clinical application, Fitzmaurice is also an advocate—particularly in areas where stigma or lack of awareness can hinder care. One such area is male breast cancer, a condition often overlooked or underreported. Through his work with cancer survivors, he has observed how denial and social perceptions can delay diagnosis and treatment. “The most important thing is not to be in denial. When people avoid acknowledging a diagnosis, they miss the opportunity to access the care and support that could help them.”

He emphasizes that survivorship programs and supportive care models must be inclusive and accessible to all patients. “We need to create a space where everyone feels included—especially men—because the rates are rising, and the need is real.”

 

Collaboration and Leadership in a Growing Field

Fitzmaurice’s work is strengthened by his collaborations with leading voices in oncology and exercise science, including Dr. Jay Harness, a former oncologic surgeon who has become a strong advocate for exercise-based interventions in cancer care.

Their partnership reflects a powerful convergence of clinical oncology and performance science. “When I learned about Dr. Harness’s history—over 30 years as an oncologist—and his commitment to exercise oncology, it opened my eyes to how impactful this field can be.” Together, they are contributing to publications and initiatives aimed at advancing exercise as a recognized and standardized component of cancer care.

 

The Future: Research, Education, and Systemic Change

Looking ahead, Fitzmaurice is committed to further advancing the field through research and education. He plans to pursue a PhD with a focus on exercise oncology, with the goal of strengthening the scientific foundation that supports its integration into clinical practice. “I want to help build the evidence that ensures cancer survivors receive the level of care they deserve—and that practitioners know how to implement exercise properly.”

His long-term vision is clear: to influence healthcare systems, inform clinical guidelines, and ensure that exercise is no longer considered optional, but essential.

 

A New Standard in Cancer Care

Christopher Fitzmaurice embodies a shift in modern medicine—one that prioritizes proactive, integrative, and patient-centered care. With a unique blend of clinical expertise and human insight, he is helping to redefine the role of movement in oncology.

In his model, exercise is not an afterthought. It is a strategy. A therapy. A lifeline. As research continues to validate what practitioners like Fitzmaurice have long understood, the future of cancer care will increasingly embrace this approach—where healing is not only delivered through treatment, but cultivated through movement, strength, and resilience.

And in that future, exercise will not simply support recovery—it will help define it.



 


Aftermath

On Exercise as a Clinical Ally in Cancer Recovery

By Robert L. Bard, MD, DABR, FAIUM, FASLMS

As a diagnostic imaging specialist, my role has always centered on identifying disease—locating it, defining it, and understanding its behavior. But over the years, one of the most important realizations in oncology has been this: detection is only the beginning. What follows—how the body responds, heals, and adapts—defines the patient’s true outcome.

In this context, exercise has emerged as one of the most valuable yet historically underutilized tools in cancer care.

From a clinical standpoint, cancer and its treatments impose a profound physiological burden. Chemotherapy, radiation, and surgical interventions often leave patients with decreased muscle mass, impaired circulation, chronic inflammation, and significant fatigue. These are not secondary issues—they directly influence recovery, resilience, and long-term survival.

What professionals like Christopher Fitzmaurice are advancing through exercise oncology is a critical shift in how we approach this recovery phase. Exercise is not simply about fitness. It is about restoring function at a cellular and systemic level.

We now understand that structured physical activity improves vascular circulation, enhances oxygen delivery, and supports lymphatic flow—key mechanisms that help the body clear metabolic waste and reduce inflammatory burden. From an imaging perspective, we often correlate improved blood flow with better tissue health and recovery potential. Movement, quite literally, fuels healing.

Equally important is the role of exercise in preserving muscle integrity and metabolic stability. Loss of strength is one of the most overlooked consequences of cancer treatment, yet it is directly tied to a patient’s independence and long-term prognosis. Rebuilding that strength is not cosmetic—it is foundational to survival.

There is also a neurological component that cannot be ignored. Physical activity stimulates neurochemical pathways associated with mood, cognition, and resilience. Patients who engage in structured exercise programs frequently demonstrate improved mental clarity and emotional stability—factors that are essential when navigating the psychological weight of a cancer diagnosis.

From a rehabilitation standpoint, exercise bridges the gap between treatment and true recovery. Traditional rehab often addresses isolated impairments, but exercise provides a global, integrative benefit—supporting cardiovascular, musculoskeletal, and neurological systems simultaneously.


Most importantly, exercise introduces agency back into the patient experience. Cancer treatment can often feel passive—patients receive therapies, undergo procedures, and wait for results. Exercise shifts that dynamic. It gives patients an active role in their own recovery, reinforcing both physical capability and psychological empowerment.

As we look toward the future of oncology, it is clear that multidisciplinary collaboration will define the highest standard of care. Imaging, medical treatment, rehabilitation, and performance science must work together—not in silos, but as an integrated system.

Exercise oncology is not an alternative concept. It is a necessary evolution.



 

 Reprise: Exclusive from HealthTech Reporter


ReBuilding to Last: Strength, Longevity, and the Technology That Multiplies Human Potential

An exclusive interivew with ELLEN TYSON

Written by: Lennard M. Goetze, Ed.D


ELLEN TYSON
 does not frame fitness as vanity. She frames it as survival, agency, and long-term independence. A strength training coach and Visionbody brand evangelist, Tyson speaks with the authority of lived experience: the arc of her life reshaped by movement after decades of chemical depression, and later refined by a clear-eyed understanding of what aging demands of the body. Her message is simple but uncompromising: muscle is the infrastructure of longevity. “Muscle is your biggest organ of longevity,” Tyson says. “Before supplements, before vitamins—build your muscles.” For Ellen, strength training is not a trend. It is preventive medicine. 

 

FROM SURVIVAL TO STRENGTH: A PERSONAL TURNING POINT

Tyson’s path into strength training was not born of aesthetics or athletic ambition. For much of her adult life, she managed recurring chemical depression. In her forties, she discovered that consistent exercise did something medication never fully achieved: it stabilized her mental health. “Since I was 44… I have not had a depressive episode,” she explains. “I’ve been sad, but not the chemical depression that sent me over the edge every couple of years.”

What began as a social activity became a physiological reset. Over time, she recognized a deeper pattern: movement changed not only her mood, but her metabolism, bone density, and resilience. This realization reframed fitness from self-improvement to self-preservation. “Resistance training is preventative medicine,” she says.

As her children grew older, Tyson transitioned into professional training. The work resonated because it mirrored her own transformation. She no longer trained clients for appearance. “I care not what I look like in a bikini… I care about being strong and healthy. The byproduct is the lean body.

The outcome is functional longevity: the ability to walk well, recover faster, and remain metabolically active with age.

 

STRENGTH AS THE SPINE OF LONGEVITY

Tyson’s philosophy rests on a clinical truth increasingly supported by research: skeletal muscle is a metabolic organ that influences glucose control, immune competence, hormonal balance, and bone density. As muscle declines with age (sarcopenia), risk rises for falls, insulin resistance, and frailty. Tyson compresses this science into lived wisdom: “Once your muscles go, your immune system goes down, your bone density goes down—everything goes.

For postmenopausal women, the stakes are higher. Hormonal shifts favor visceral fat gain, accelerate bone loss, and slow recovery. Tyson frames muscle as the first line of defense. “For postmenopausal women… the first line of defense always is muscle.

Her guidance is not punitive. It is practical: build the engine that supports every other system. She also confronts the most common barrier—time. “If you don’t take time for your wellness, you will be forced to take time for your illness.

In this framing, exercise is not an added burden; it is a protective investment against the future cost of disease.

 

VISIONBODY: WHEN TECHNOLOGY MULTIPLIES EFFORT

Tyson’s role as a Visionbody brand evangelist grew out of years of experience with electro-muscle stimulation (EMS). Visionbody’s wireless suit delivers
low to mid frequency
electrical stimulation to contract muscles deeply during movement, amplifying conventional training. The suit engages most major muscle groups in short sessions, turning 20 minutes into a comprehensive workout.

What differentiates Visionbody in Tyson’s account is depth and comfort. She contrasts higher-frequency stimulation with older EMS systems that sting and work superficially. The Visionbody platform, she explains, reaches deeper muscle layers, increasing oxygen demand and circulation. “It engages, activates your muscles deep and hard—more than you can on your own.

This physiological load accelerates adaptation while preserving joint safety. For busy professionals and older adults, efficiency matters. “It’s a 20-minute workout. It maximizes your time.” Tyson notes.

In her practice, the suit does not replace training—it sharpens it. She still coaches form, balance, and progressive loading. Technology becomes a multiplier, not a shortcut. The platform’s clinical applications extend beyond fitness. Tyson describes medical protocols for individuals with limited mobility—patients in wheelchairs, neurological conditions, or prolonged bed rest—where stimulation can help maintain circulation and reduce muscle atrophy.

This dual-use design—performance and rehabilitation—reflects her broader belief that wellness tools should scale across health states, not only serve the already fit.

 


STRENGTH AS REHABILITATION, NOT JUST PERFORMANCE

In conversations with clinicians, Tyson emphasizes how muscle preservation intersects with recovery from illness and cancer treatment. She references Visionbody’s origins in survivorship and rebuilding after severe muscle loss. Increased circulation and oxygenation, she notes, support cellular recovery.

While not a medical cure, strength training—augmented by EMS—becomes a rehabilitative bridge back to autonomy. Her coaching style remains cautious with vulnerable populations. Stimulation intensity is titrated; progression is gradual. “Too much of a good thing… you can actually deteriorate muscles if you go too strong.  The principle mirrors her longevity ethic: sustainable gains beat dramatic but brittle progress.

 

THE EDUCATOR’S ETHIC: TEACHING AGENCY

Tyson’s influence is not confined to training sessions. She identifies as an educator, translating physiology into habits people can sustain. Her most repeated lesson is behavioral: the hardest part is showing up. “The hardest part about working out is actually getting to the gym. Once you’re there, you’re motivated.

 This framing lowers the psychological barrier to action and builds consistency—the real driver of results. Her messaging to midlife women is resolute and hopeful. “It’s never too late to build muscles.”  She positions strength as a reclaiming of agency during hormonal transitions often framed as decline. In doing so, she reframes longevity as something practiced daily, not postponed to later interventions.

WHY ELLEN TYSON RESONATES

Tyson’s authority is not performative. It emerges from congruence: she practices what she teaches. Her body becomes evidence, but her story carries the proof. She connects mental health, metabolic health, and musculoskeletal resilience into a single narrative of self-stewardship. Technology fits into this arc not as spectacle, but as a pragmatic amplifier of effort. “I don’t understand people who wait until they’re sick to take care of their health,” she says.

In her framework, the body is not a machine to fix when broken; it is an ecosystem to support while it’s working.


THE TAKEAWAY

Ellen Tyson’s message to the longevity movement is blunt and humane: build muscle to protect your future self. Pair disciplined training with smart tools like Visionbody when appropriate. Treat strength as infrastructure—for balance, immunity, bone density, recovery, and mental health. And begin now, not later. Her ethic closes the loop between effort and technology, prevention and performance, body and agency. Strength training, in her view, is not about aesthetics, but actually being powerful from the inside an out. It is about staying capable—long enough to keep living well, longer.




WHERE ENERGY MEETS EVIDENCE: Imaging the Physiology Of Strength And Recovery

This February, Ellen Tyson of Visionbody and Dr. Robert Bard will collaborate on a focused performance review and medical validation initiative examining the clinical impact of Visionbody’s EMS muscle-strengthening technology. The project is designed to move beyond anecdotal claims by applying objective diagnostic imaging and monitoring protocols to evaluate measurable physiological change.

Dr. Bard’s interest centers on imaging-guided assessment of EMS-driven energy induction and its real-world effects on neuromuscular activation, muscle strength development, tissue response, and functional regeneration. Of particular interest is how EMS may influence neuromuscular signaling pathways associated with neurotransmitter activity and recovery mechanisms—areas that are increasingly relevant to aging populations, rehabilitation, metabolic dysfunction, and post-treatment recovery.

Throughout February, performance data will be documented through serial monitoring and imaging-based observation to identify patterns of response, adaptation, and potential therapeutic relevance. This initiative reflects a growing demand for evidence-based validation of non-invasive technologies entering the clinical and wellness landscape.

Findings and clinical observations from this collaboration will be published exclusively in HealthTechReporter.com, offering clinicians, researchers, and informed patients a transparent look at how emerging EMS technologies perform under real diagnostic scrutiny.


 

 

Copyright Notice © 2025 Overture Publications. All rights reserved. This work and all materials contained herein are the intellectual property of Overture Publications under the Institute for Global Health Innovations and its authorized contributors. No part of this manuscript may be reproduced, stored in a retrieval system, transmitted in any form or by any means—electronic, mechanical, photocopying, recording, or otherwise—without prior written permission from the publisher. All names, images, and materials are protected under applicable copyright and intellectual-property laws in the United States and internationally. Any reference to individuals, institutions, or proprietary entities is for informational purposes only and does not imply endorsement or affiliation unless expressly stated. All trademarks and service marks mentioned are the property of their respective owners.

If our goal is not only to extend life but to improve the quality and strength of that life, then exercise must be recognized as a central pillar in cancer recovery, rehabilitation, and ultimately, longevity.





Tuesday, May 13, 2025

Pennsylvania's HB433 Advances: A Landmark Bill for Breast Health Equity Unanimously Passes the House

By Lennard M. Goetze, Ed.D – AngioMedical News

In a significant step toward improving breast health care equity in Pennsylvania, House Bill 433 (HB433) passed the Pennsylvania House of Representatives with a resounding 198-5 vote on May 12, 2025. This pivotal legislation, aimed at expanding insurance coverage for diagnostic breast examinations without cost-sharing barriers, represents a victory for patients, advocates, and healthcare providers alike.

Background: The Need for HB433
The origins of HB433 trace back more than a year, when Cheri Ambrose, Founder and President of the Male Breast Cancer Global Alliance, reached out to the Pennsylvania Governor’s office and legislative stakeholders to advocate for improved access to breast imaging services — not just for women, but for all individuals, including men diagnosed with or at risk for breast cancer.

Historically, state insurance mandates have focused on screening mammograms, often leaving significant gaps in coverage for diagnostic follow-ups like MRIs, ultrasounds, and diagnostic mammograms when abnormalities are detected. This has led to financial strain and delayed diagnoses for many patients, particularly men with breast cancer, a group frequently overlooked in traditional breast health policy.

Recognizing this, the House Democratic Insurance Committee began work on HB433, designed to ensure that both screening and diagnostic breast imaging would be accessible without burdensome out-of-pocket costs — a move aligned with updated guidelines from the U.S. Health Resources & Services Administration (HRSA) and federal health insurance mandates set to take effect in 2026.

The Legislative Process: Stakeholder Collaboration and Amendment
On March 26, 2025, Joseph Keller, Senior Research Analyst for the House Democratic Insurance Committee, formally reached out to stakeholders for feedback on both the bill and a proposed amendment (A00204). This amendment refined HB433’s language to enhance its inclusivity and legal precision. Key changes included:

Replacing gendered language: Substituting “women” with “individuals” to ensure breast health coverage for all, regardless of gender.

Clarifying insurance applicability: Modernizing outdated legal references and definitions within Pennsylvania’s mammogram law.

Defining covered costs: Clearly stating that “all costs” would include copayments, coinsurance, and deductibles — with exceptions for certain high-deductible health plans tied to Health Savings Accounts.

Aligning with HRSA guidelines: Ensuring diagnostic breast examinations would include MRIs, ultrasounds, or diagnostic mammograms for any suspected abnormalities detected in initial screenings.

Cheri Ambrose remained an engaged advocate throughout the process, communicating regularly with Keller and other House staff to monitor progress. After a successful committee adoption of the amendment in April 2025, the bill was scheduled for a final House vote in May.


Final Passage and What Comes Next

On May 12, 2025, the Pennsylvania House of Representatives Led by House Speaker Rep. Joanna McClinton amended the historical act of May 17, 1921 (P.L.0682, No.0284), known as the "Insurance Company Law Of 1921. The house voted overwhelmingly in favor of HB433. Cheri Ambrose received confirmation of the vote directly from Joseph Keller, who expressed appreciation for the ongoing advocacy and stakeholder input that helped shape the bill’s passage. The bill now moves to the Pennsylvania Senate for further consideration. If approved there, it will proceed to the Governor’s desk for final enactment. “No one should have to go into debt to access the health care they need, but high out-of-pocket costs can discourage people from seeking care", states Rep. McClinton. By passing HB 433 this week, the state House took action to help more Pennsylvania men and women access diagnostic breast imaging which can save lives and reduce the overall costs to our state’s healthcare system.”

(L-Image) Representative Gina H. Curry - PA General Assembly also shared her statement about the recent historical legislative amendment. “Breast cancer does not discriminate, and neither should access to care. Men get breast cancer too, fathers, brothers, sons, yet many delay care due to stigma or cost. HB 433 ensures that if you find a lump, you can get answers no matter your gender, zip code, or bank account. Black and Hispanic women are more likely to be diagnosed at later stages and have higher mortality rates. Black women are 2.7 times more likely to face triple negative breast cancer and 28 percent more likely to die from it. This bill tears down the financial walls that keep people from getting the diagnostic tests they need. We are not just saving women’s lives, we are saving lives, period. Because cancer does not wait, and neither should we."


What This Means for the Public
For the public — particularly those affected by or at risk for breast cancer — HB433 represents a monumental step forward. Should it become law, Pennsylvanians will no longer face the burden of out-of-pocket costs for essential diagnostic breast exams if abnormalities are detected during initial screenings. This legislation ensures insurance plans offered, issued, or renewed in the Commonwealth will cover these vital services, aligning state law with evolving federal preventive care standards.

Importantly, by adopting gender-neutral language and including men within the framework of breast health care policy, HB433 acknowledges the realities faced by male breast cancer patients, a demographic long overshadowed in public health conversations.


Conclusion
HB433’s progress exemplifies the power of advocacy, stakeholder collaboration, and responsive legislation. As Pennsylvania moves one step closer to codifying these protections into law, advocates like Cheri Ambrose and legislative champions within the House Insurance Committee offer a clear reminder of what dedicated, patient-centered policy work can accomplish.

For more information on male breast cancer and ongoing advocacy initiatives, visit the Male Breast Cancer Global Alliance.


Sunday, October 27, 2024

"GET SMARTER ABOUT CANCER" - Lecture Series- feat. Dr. Joshua Berka

FOREWORD
By: DR ROBERT L. BARD, Cancer Diagnostic Imaging Specialist

For the many Americans who seek a significantly improved lifestyle or an upgrade in personalized healthcare, getting better answers about our state of health is paramount. What goes into our "standard of care" is no longer acceptable to the the vast majority of general consumer. These same consumers have since been educated in what's available as far as intelligent alternative modalities from highly qualified and educated professionals that have proven wellness success in their respective specialty practices. The visionary paradigm that makes up FUNCTIONAL MEDICINE is defined as individualized medical care that recognizes the interactions between genetic and environmental factors and between the body's interconnected systems. True personalized care is patient-centered care. Subscribing to a FUNCTIONAL TESTING, MONITORING AND DIAGNOSTIC STRATEGY offers the ideal launch pad to a platform of true wellness and disease prevention.  It is for this innovative minset to problem-solving that we are proud to welcome Dr. Joshua Berka as one of the "Get Smarter about Cancer" lecture series. 

Dr. Berka is double board-certified and licensed Naturopathic Doctor (ND) and Acupuncturist (L.Ac.) as well a Certified Functional Medicine Practitioner (FMCP). He is passionate about Integrative, Preventative, Functional and Regenerative Medicine and is an advocate for personalized patient-centered care. Dr. Berka has been in clinical practice for 17 years and serves as a medical consultant supporting innovative medical technologies that non-invasively improve patient treatment outcomes as well as adjunctive therapeutics that can be used as a part of a healthy lifestyle. Dr. Berka has been a consultant within the med-tech space for the past 15 years and currently consults for BEMER Group (news source- Medium.com)


DIRECT FROM THE INTERVIEW
transcript by: Dr. Joshua Berka
 (10/25/2024)

I had the opportunity to work in the integrated field when I was in Los Angeles for over seven years, and to integrate the field of in integrative oncology. I trained more naturopathically functionally. Before we can get into the recurrence aspect, we have to look at the manifestation of this. Sure, we all have cancer in our body, but why this person expresses versus the next person, (and it's not just the genes), it's how those genes are being expressed. And so many cases exist within women's cancers -especially breast cancer. A lot of this is not just from the genetics- this is only one piece of this. 

Another factor is that the victim maybe not able to circulate or clear out metabolic waste products. Our estrogens (both men and women) are broken up, built up and they're all built from cholesterol.  And those metabolites can be sometimes a hundred times more toxic than the estrogens themselves. If that individual doesn't have the detox capacities, and then they're overwhelmed with, for instance, things within their environment, this sets up the perfect storm for that individual to have the (gene) expression. 

I don't care if they're treated with conventional chemotherapy radiation; the root cause has not been addressed. And in this particular case, it's a hetero or a homozygous type of situation where they can be supportive in their ability to metabolize and clear those detrimental waste products, those metabolic waste products. So it might basically be something that is supporting the gene expression for a little gap versus thinking that cancer is here. 

Let's use a targeted therapy (which is not really targeted in many cases) to take out that which is a disease. And from my perspective, I want to talk about cancer. As far as solid tumors (as opposed to lymphomas, leukemias and the like)- every time I have looked under my microscope looking at cancer or looking at measurements like Dr. Bard is doing, he's really looking functionally with ultrasound in real time during therapeutic interventions. I've done a lot of the same over the years and what I found, (without a doubt) is carcinogenic tissue is not functioning at the same level of energy production. 

So back to bioenergetics mitochondria as healthy tissue, maybe we can envision it this way. This is how stem cells used to be replicated. Imagine, I mean, it's the season, it's the fall. All the trees are dropping their leaves and pine cones are dropping.  They're doing this because winter is coming and that species and that grouping may not make it through another winter. So in hopes of survival.  It's actually seeding its environment. If you take energy or you take a cell out of the body and you expose it to an environment that doesn't have fluid (dry), one of the first things it starts to do before it apoptosis is it actually starts to replicate. It differentiates into an embryological state and then starts to replicate. These cells are not necessarily functional, but it's a response/reaction to these environmental signaling.  When treating individuals with cancer (not treating cancer) my primary goal is to target the mitochondrial bioenergetics and the functional utilization and transformation of energy with an individual. 

Courtesy of Aspen Laser
And many times those tumors will actually apoptose on their own once you start raising the energy around it. What types of medical devices do this?  Diet, food, positive thinking, neutral thinking. Lasers directly can input PHOTOBIOMODULATION photons into electron raising the electron transport chain to raise the zeta potential of erythrocyte or the outside membrane potential of a cell pulse. 

ELECTROMAGNETIC field therapy can also wirelessly inductively charge up these cells. So I think down the road, we have to rather look beyond a "kill, kill, kill" concept with these cells, and reintegrate  and reprogram those cells back into the system.  

What I was doing (research) was homing stem cells, enacting programming information into cells, not just with wireless signals but also with PEPTIDES. You don't need a viral vector to deliver that. You can actually deliver the signal in many ways, wirelessly or through aspects of light.    --- To be continued---

Video News Release: Innovations in Early Detection

"Are You Dense?" Foundation Co-founder Joe Cappello joins the medical diagnostic community to promote the "Get Checked Now!" campaign. Dr. Robert Bard from the Bard Cancer Center (NYC) supports supplemental imaging including the 3D Doppler Ultrasound scanner to offer dense breast detection.  This video presents some of the latest advancements in ultrasound features to detect tumors through dense breast tissue- reportedly a significant challenge with mammograms. 

PREDISPOSITION
So when I look at the predisposition of an individual, I don't just look at it from a structural perspective. There's the mental/emotional aspects, socioeconomics- and even down to a spiritual aspects. Unfortunately (or fortunately in some ways), these predispositions aren't just inherited on a genetic level. They're actually learned behaviors that we've observed from people who are close to us.  But we've perceived as close who are around us, and "living styles" and habits- ways that we've learned to cope with stress in either a functional way or in a dysfunctional way. And so, when I look at this predisposition, it's a combination of elements- and not just "that's my parents' fault... these are the genes I got!". Unfortunately, that game's NOT TRUE. This it's a bit of 'MYTHinformation' because yes, you do have the propensity to express in a certain way, but not necessarily the predisposition. 

That predisposition is a series of events or decisions that are made to allow that to be expressed. So why some people smoke their whole life and they don't get cancer, well is because they're not predisposed for that in essence.  The predisposition of each individual needs to be really looked at on a personalized level of uniqueness-- what I just call PERSONALIZED PATIENT CENTERED MEDICINE. Rather than saying "here's the disease", let's find out exactly how you got it.  It's important to find out the ideology of the cause, but it's more important to talk about RECURRENCE to prevent something that's occurred, even though when it was perceptually treated.  

We can identify our predispositions or possibilities of (gene) expression of both health or disease by looking at the parents and you could say, oh, this person died of heart disease or ovarian cancer.  But more so with early diagnostics, you can start looking at not just the genomic profiles, but you can start looking at functional diagnostics at a level of blood testing or saliva testing, looking at adrenal function, even looking at bits of certain types of carcinogenic DNA that's floating through the blood. From that perspective of predisposition, we can PREDICT nature. Once you know the predisposition of an individual, then you can predict the potential outcome. 

It's going to be harsh for a lot of the doctors out there and is something that I've observed. (If you can prove me wrong, I ask you, please do so). This aspect of ANABOLIC versus CATABOLIC metabolism. Generally, cancer patients with a solid state tumor status are in a SYSTEMIC aspect of anabolic metabolism. 

They're kind of stuck. #1: Cancer is a tumor, but it's a systemic disease. We have to understand this. #2: Cardiovascular disease or heart disease is more of a catabolic type of disease. So catabolic versus anabolic. I want to know if there's anybody who has ever seen cancer and heart disease happening simultaneously other than prostate cancer. This is a call out to the world. And I'm asking this because if we can just look at fundamental, basic anabolic catabolic cycles.  We may be able to push these metabolic cycles- not just through diet, sleep & wake cycles, but also lifestyle medicine. 

Most of lifestyle medicine is free. It doesn't cost a penny. 




Saturday, September 21, 2024

RECURRRENCE EXPLAINED
ADVOCACY & JOINING HANDS TO MAKE A DIFFERENCE
By: Geri Barish -  Hewlett House (Cancer Resource)

Getting the word out is vital when it comes to supporting our community in the fight against cancer.  Part of the search for answers is learning how to assess your own life - including your history, the area where you live, what you eat, what you breathe and your genetic blueprint. This may lead to identifying any kind of cancer in the family.  

Staying vigilant in understanding how cancer happens and how it affects us and our families is the key to awareness. Advocacy is also about supporting one another. As we wait for the cure, we also need to live a full life- this includes staying proactive with our health and staying in touch with the latest solutions. There's a lot more work to be done- and because we are fighters, we have to keep asking questions. Look at your environment- get genetic testing for gene mutation in your lineage, don't ignore checkups- find out if you have any risk factors. That's where education and research comes together. And if you've had cancer already, please don't think it won't come back. Recurrence (or re-occurrence) is a real term- and when it happens, it can come back with a vengeance. 

There is a constant debate in the cancer community about the term "CANCER FREE". Cancer recurrence continues to be a major concern as reported in annual medical reports- identifying its tendency to “return with a vengeance". [1, 2]

Medical research has identified the major reasons why cancer recurs.  A widely reported cause for this is attributed to a deficiency in treatment performance. [2] This means the therapy induced did not successfully remove or kill all of the cancer cells, possibly due to the patient's level of drug resistance.  During treatment, Cancer cells can enter a dormant state to protect themselves from treatment and other stimuli. Over time, these dormant cells can reactivate. The cause of this may be a spike in chronic stress or the release of toxins from oxidative stress from environmental factors like smoking or repeat exposure to reactive chemicals. [3]

Inflammation has also been linked to the activation of immune cells called neutrophils. [4] Cancer cells that have spread to other areas of the body after successful treatment of the original tumor can remain dormant for years or decades before recurring as metastatic cancer. Further activators of these dormant cells have also been linked to one's personal Epigenetics. [5] This determines how your environment and lifestyle affects your cell function- including the dormancy state of your cancer cells. 

Another known cause for recurrence are Cancer stem cells or CSC's.  These are a small group of cells in tumors that have the ability to self-renew, differentiate, and give rise to all cell types in a tumor. [6] Most stages of tumor progression, including tumorigenesis, promotion, progression, and recurrence are accompanied by epigenetic alterations, some of which can be reversed by epigenetic drugs. [6]

DETECTION MONITORING
After cancer surgery, there are many preventive measures to support a safe and healthy recovery and to reduce the risk of recurrence.  A logical and preventive strategy as part of postop maintenance is called RECURRENCE PREVENTION SCANS. Through the use of affordable, real-time medical imaging such as the 3D Doppler Ultrasound, post-cancer surgery patients can subscribe to a personal monitoring regimen to scan for any potential lesions and micro-tumors that may have fallen under the radar.  Proactive monitoring can also address complications such as post-surgical Infections, recurring pain, swelling, neuropathy from nerve damage, scarring, fluid buildup or blood clots. In less than 20 minutes per visit, you earn peace of mind from a comprehensive scan by seasoned specialists trained to support postop patient management.

(1) Butow P, Sharpe L, Thewes B, et al. Fear of Cancer Recurrence: A Practical Guide for Clinicians. Oncology (Williston Park). 2018 Jan 15;32(1):32-8. (2.) Mahvi DA, Liu R, Grinstaff MW, et al. (2018). Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies. CA: A Cancer Journal for Clinicians, 68(6), 488. https://doi.org/10.3322/caac.21498 (3.)Payne KK. Cellular stress responses and metabolic reprogramming in cancer progression and dormancy. Seminars in cancer biology 2022 Jan Vol. 78, pp. 45-48. (4.) He X-Y, Gao Y, Ng D et al. Chronic stress increases metastasis via neutrophil-mediated changes to the microenvironment. Cancer Cell 2024:42(3);474-486. DOI: https://doi.org/10.1016/j.ccell.2024.01.013  (5.) Costa S, Alves Sales SL, Pinheiro DP, et al. (2023). Epigenetic reprogramming in cancer: From diagnosis to treatment. Frontiers in Cell and Developmental Biology, 11. https://doi.org/10.3389/fcell.2023.1116805 (6.) aYu X, Zhao H, Wang R, et al. (2024). Cancer epigenetics: From laboratory studies and clinical trials to precision medicine. Cell Death Discovery, 10(1), 1-12. https://doi.org/10.1038/s41420-024-01803-z
ROBERT L. BARD, MD  (Diagnostic Imaging Specialist)
Having paved the way for the study of various cancers both clinically and academically, Dr. Robert Bard co-founded the 9/11 CancerScan program to bring additional diagnostic support to all first responders from Ground Zero. His main practice in midtown, NYC (Bard Diagnostic Imaging- www.CancerScan.com) uses the latest in digital Imaging technology has been also used to help guide biopsies and in many cases, even replicate much of the same reports of a clinical invasive biopsy. His most recent program is dedicated to the reporting of mental health diagnostic and innovative solutions including the use of modern neuromagnetic technologies and protocols in his MEDTECH REVIEWS program. www.BardDiagnostics.com

ROBERTA KLINE, MD (Educational Dir. /Women's Diagnostic Group)
Dr. Kline is a board-certified ObGyn physician, Integrative Personalized Medicine expert, consultant, author, and educator whose mission is to change how we approach health and deliver healthcare. She helped to create the Integrative & Functional Medicine program for a family practice residency, has consulted with Sodexo to implement the first personalized nutrition menu for healthcare facilities, and serves as Education Director for several organizations including the Women’s Diagnostic Health Network, Mommies on a Mission. Learn more at https://bobbiklinemd.com 




HealthTech Reporter and Fight Recurrence brings you the conclusion of JIM HUNT's 6-Year personal journey report about his battle against early Prostate Cancer.  After years of ACTIVE SURVEILLANCE, a recent uptick in tumor size (5mm) was time enough to "do something more proactive about my cancer!".  Jim has been a prominent researcher on the topic of cancer care since his wife survived breast cancer 20 years ago. Today, his exploration led him to recognize the benefits of non-invasive cancer treatments including the advancements of radiation therapy such as PROTON BEAM therapy. (See his mini-documentary video: DAY 5/ Final Treatment day)